Jun 6, 2011 – BioSante Pharmaceuticals, Inc. (Nasdaq:BPAX) announced completion . new drug application (NDA) submission anticipated to be made in 2012. .

Feb 3, 2011 – (NASDAQ: BPAX ) for investors following biotech and pharma stocks. . . BioSante `s obective is to submit the LibiGel NDA in 2011 for a .

BPAX.A on American Stock Exchange 2.12USD 18 Apr 2011 . . BioSante's objective is to submit the LibiGel NDA for a product launch in 2012. Full Article .

Apr 13, 2011 – Find the latest stock activity of the day with our stock market summary on Boston.com.

BioSante (NASDAQ: BPAX) is a specialty pharmaceutical company focused on . for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral .

Sep 30, 2009 – The Company is targeting its submission to the FDA of a NDA during . women as BPAX is focused on with its three ongoing Phase 3 studies). .

Nov 2, 2010 – BioSante's objective is to submit the LibiGel NDA in 2011. . About BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)BioSante is a specialty .

Jun 27, 2011 – However, BioSante intends to submit a LibiGel NDA for review and . is paid for as part of the BPAX showcase program (two thousand per .

Jul 22, 2011 – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for July 22 nd . . which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral .

Aug 7, 2011 – . LibiGel new drug application (NDA) submission by the end of 2012, . Request news, updates and trading alerts on BPAX and other .

Nov 3, 2010 – http://www.investorideas.com/CO/BPAX/news/9211.asp . According to your press release, A new drug application (NDA) can be submitted after .

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug .

BPAX - Biosante Pharmaceuticals Inc. - SocialPicks. . has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, .

Mar 24, 2011 – Al Capone's Vault Message: BPAX - NDA filing and completion of the.

Click here for ClinicalTrials.gov listings for BPAX (incomplete - does not include . from BPAX management; NDA submission: Prior guidance had been for NDA .

Apr 13, 2011 – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. .

Apr 14, 2011 – LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) reports a .

Jul 19, 2011 – . position in it as the timeline approaches for the NDA and phase III continues. . 106, BPAX reached Stop (Closing Long Recommendation) .

Apr 21, 2011 – Recent News for Bio-T-Gel: Bio-T-Gel NDA pending with PDUFA date of . The full BPAX company profile is available at Investorideas.com .

BPAX. Get real-time alerts. Biosante Pharmaceuticals, Inc. 8/22/2011, 9:42 AM ET . With respect to Elestrin, we submitted an NDA in February 2006 and .

BioSante Pharmaceuticals (NASDAQ:BPAX) has closed a public offering of 16 million common shares at a price of . 14, 2011 to complete its review of the NDA. .

1 post - 1 author - Last post: Sep 28, 2009Hey Guys, If you are in BPAX or CEGE this article by Mike Havrilla . The Company is targeting its submission to the FDA of a NDA during .

Apr 4, 2011 – Default BPAX BioSante Pharmaceuticals, Inc. . BioSante can use the safety study data as part of an NDA submission after an average of 12 .

03:13PM, Friday Options Brief: ADM, TRW, RDWR & BPAX at Seeking Alpha . . 07: 55AM, InPlay: BioSante announces Teva NDA for Bio-T-Gel Briefing.com .

Apr 25, 2011 – We are extremely excited by Tevas NDA filing of Bio-T-Gel said Stephen M. . Disclosure Disclaimer/ BPAX is a paid advertising client on .

Read more: BioSante (BPAX): LibiGel Statistical Rundown . The good news is that the FDA has accepted their NDA for Acurox Tablets as a Priority review .

May 10, 2011 – Biotech News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports First . Bio-T- Gel™ New Drug Application (NDA) Filed by BioSante Licensee, .

Apr 13, 2011 – Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Teva New Drug Application (NDA) for Testosterone Gel, Bio-T-Gel .

Jun 8, 2011 – an NDA will be submitted to obtain marketing approval" Todays news is in direct contradiction to above. I would have to believe that BPAX .

Apr 27, 2011 – BioSante Pharmaceuticals, Inc. (Nasdaq: BPAX) announced that a New Drug Application (NDA) for Bio-T-Gel has been accepted for filing by .

Jul 18, 2011 – Request news, updates and trading alerts on BPAX and other showcase stocks . Watson-Columbia Drug's NDA Accepted. Posted on July 20, 2011, .

Jul 22, 2011 – . Inc. (NASDAQ: BPAX), IJJ Corporation (OTCPK: IJJP), . for which an NDA is pending, licensed to Teva Pharmaceuticals, .

Apr 13, 2011 – Biosante Pharmaceuticals , Inc. (NASDAQ: BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. .

BioSante Pharma (NASDAQ: BPAX) is a specialty pharmaceutical company . 2009, BioSante has sufficient cash on hand to make its way through a NDA filing .

Mar 4, 2011 – With respect to Elestrin, we submitted an NDA in February 2006 and . .. stock is listed on the Nasdaq Global Market under the symbol “BPAX. .

Aug 9, 2011 – . new drug application (NDA) submission by the end of 2012, and in fact all . Request news, updates and trading alerts on BPAX and other .

AFF submit NDA for peginesatide, BPAX NDA filing possible late 2012, YMI ASTM: Affymax, Inc. (NASDAQ:AFFY) and Takeda Pharmaceutical Company Limited .

Feb 13, 2011 – If you've followed BPAX for awhile, you know that the estimated date of NDA filing has constantly slipped backward. This weekend's press .

Oct 27, 2010 – A new drug application (NDA) can be submitted after an average of 12 months of . . Visit the BPAX showcase profile at Investorideas.com .

Dec 28, 2010 – Our objective is to submit a new drug application (NDA) to the . . is paid for as part of the BPAX showcase program (three thousand per .

Aug 9, 2011 – . LibiGel new drug application (NDA) submission by the end of 2012, . Request news, updates and trading alerts on BPAX and other .

Apr 14, 2011 – Your Story | ( .com newswire) Pharma stock news; BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) reports a New Drug Application (NDA) has been .

BIOSANTE PHARMACEUTICALS INC (BPAX:US) stock price & investing information. .

5 posts - 4 authors - Last post: Apr 19is due in May 2011 with anticipated NDA in June. It has a 98% efficacy profile . Invested in both and hope BPAX ultimately takes off lik. .

Apr 13, 2011 – Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Teva New Drug Application (NDA) for Testosterone Gel, Bio-T-Gel™ .

May 18, 2011 – BPAX has a very high concentration of calls in September and December to the . Fundamentally this appears bullish since P3 data and an NDA .

I want to share "Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Teva New Drug Application (NDA) for Testosterone Gel, Bio-T-Gel™" via .

Dec 5, 2010 – We have added Biosante Pharmaceuticals, Inc. (BPAX): Nasdaq to our . Inc. Hopes to announce the submission for a NDA application for the .

BPAX - BioSante Pharmaceuticals About BioSante Pharmaceuticals, Inc. BioSante is . (NDA) to obtain marketing approval and then continue with a 48-month, .

Shares of BioSante Pharmaceuticals Inc. (NASDAQ: BPAX) shares spiked as much as . approval for the filing of New Drug Application (NDA) for its Bio-T-Gel, .

Sitemap